This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• Datamonitor Healthcare estimates that in 2021, there were 591,200 incident cases of thyroid cancer worldwide, and expects that number to increase to 625,900 incident cases by 2030.
• In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.1 million cases by 2030.
• The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
• There are only two industry-sponsored drugs in active clinical development for thyroid cancer, with one each in Phase I and Phase II.
• Therapies in active clinical development for thyroid cancer target carcinoembryonic antigen, the immune system, autologous chimeric antigen receptor T-cells (CAR-T), intercellular adhesion molecule-1, stem cells/other cell therapies, and T lymphocytes. One of the two therapies is being tested in a subcutaneous formulation, while the route of administration of the other is currently unknown.
• The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 42%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
• The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the thyroid cancer space is dominated by completed trials. Novartis and Pfizer have the highest number of completed clinical trials for thyroid cancer, with 27 trials each.
• Novartis leads industry sponsors with the highest overall number of clinical trials for thyroid cancer, followed by Pfizer and Roche.